Screener
TG Therapeutics TGTX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Interest expense | 16,572 | 6,716 | 24,238 | 13,473 |
| Loss on extinguishment of debt | — | — | 9,153 | — |
| Other income | (5,132) | (2,793) | (7,519) | (6,396) |
| Total other expense | 11,440 | 3,923 | 25,872 | 7,077 |
| Net income before taxes | $10,234 | $30,920 | $30,597 | $36,388 |
| Income tax expense | (2,453) | (2,733) | (3,039) | (3,141) |
| Net income | $7,781 | $28,187 | $27,558 | $33,247 |
| Net income per common share: |
Document
FAQ
- What is TG Therapeutics's other income (expense)?
- TG Therapeutics (TGTX) reported other income (expense) of -$11.44M in Q2 2026.
- How has TG Therapeutics's other income (expense) changed year-over-year?
- TG Therapeutics's other income (expense) decreased by 191.6% year-over-year, from -$3.92M to -$11.44M.
- What is the long-term trend for TG Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), TG Therapeutics's other income (expense) has grown at a 47.9% compound annual growth rate (CAGR), from -$3.33M to -$15.93M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about TG Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude